Immune to Cancer: The CRI Blog
-
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.
-
CRI Partners with the Lymphoma Research Foundation to Improve Immunotherapy Evaluation Guidelines for Lymphoma
CRI, LRF work towards better immunotherapy guidelines for lymphoma.
-
Uncovering Cancer Targets
The CRI Young Philanthropist Fellow's research on gene expression in cancer could impact the way lymphoma is…
-
Two Immunotherapies Clear Important Regulatory Hurdles
The anti-PD-1 drug nivolumab receives the go-ahead for use in Japan, while in the U.S., CAR-T cells…